(Total Views: 367)
Posted On: 03/09/2022 10:15:37 AM
Post# of 8392
ActiPatch gets Recognition in New Fortune Report
Plantar Fasciitis Market to Expand Profoundly; Approval for ActiPatch by FDA to Boost Market Revenue, says Fortune Business Insights™
03-09-2022 05:58 AM CET
"The launch of ActiPatch as drug-free pain therapy for plantar fasciitis by BioElectronics Corporation is likely to facilitate the growth of the market. For instance, in February 2017, BioElectronics Corporation received FDA approval of ActiPatch as drug-free pain therapy for plantar fasciitis and osteoarthritis which was highly efficient in treatment and demonstrated no harmful effects in patients."
https://www.openpr.com/news/2573284/plantar-f...y-approval
https://marketnewswire.live/index.php/2022/03...-insights/
Plantar Fasciitis Market to Expand Profoundly; Approval for ActiPatch by FDA to Boost Market Revenue, says Fortune Business Insights™
03-09-2022 05:58 AM CET
"The launch of ActiPatch as drug-free pain therapy for plantar fasciitis by BioElectronics Corporation is likely to facilitate the growth of the market. For instance, in February 2017, BioElectronics Corporation received FDA approval of ActiPatch as drug-free pain therapy for plantar fasciitis and osteoarthritis which was highly efficient in treatment and demonstrated no harmful effects in patients."
https://www.openpr.com/news/2573284/plantar-f...y-approval
https://marketnewswire.live/index.php/2022/03...-insights/
(2)
(0)
